| Prostate cancer is the leading
non-skin cancer killer. Over one million men have the disease and over 200,000 more are
diagnosed every year. It is a potentially lucrative disease and every serious oncology
company has a drug in trials or in development targeted at the disease. During our trip to ASCO 2003, we became aware of a
better way of understanding the treatment patterns of this disease. This new paradigm has
important consequences for the potential market of several drugs -- not to mention
important consequences for the men suffering from the disease.
This Main Story lays out our view of how
prostate cancer will be treated in the future and the impact this new paradigm will have
on oncology companies targeting this disease. |
